Logo image of LEGN

LEGEND BIOTECH CORP-ADR (LEGN) Stock Fundamental Analysis

NASDAQ:LEGN - Nasdaq - US52490G1022 - ADR - Currency: USD

39.7  +0.78 (+2%)

After market: 39.5 -0.2 (-0.5%)

Fundamental Rating

4

Overall LEGN gets a fundamental rating of 4 out of 10. We evaluated LEGN against 571 industry peers in the Biotechnology industry. The financial health of LEGN is average, but there are quite some concerns on its profitability. LEGN is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year LEGN has reported negative net income.
LEGN had a negative operating cash flow in the past year.
In the past 5 years LEGN always reported negative net income.
In the past 5 years LEGN always reported negative operating cash flow.
LEGN Yearly Net Income VS EBIT VS OCF VS FCFLEGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 200M -200M -400M

1.2 Ratios

Looking at the Return On Assets, with a value of -20.06%, LEGN is in the better half of the industry, outperforming 77.98% of the companies in the same industry.
Looking at the Return On Equity, with a value of -31.19%, LEGN is in the better half of the industry, outperforming 77.62% of the companies in the same industry.
Industry RankSector Rank
ROA -20.06%
ROE -31.19%
ROIC N/A
ROA(3y)-32.54%
ROA(5y)-33.85%
ROE(3y)-51.36%
ROE(5y)-53.16%
ROIC(3y)N/A
ROIC(5y)N/A
LEGN Yearly ROA, ROE, ROICLEGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 50 -50

1.3 Margins

LEGN's Gross Margin of 62.88% is amongst the best of the industry. LEGN outperforms 80.46% of its industry peers.
The Profit Margin and Operating Margin are not available for LEGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LEGN Yearly Profit, Operating, Gross MarginsLEGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

5

2. Health

2.1 Basic Checks

LEGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
LEGN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LEGN has more shares outstanding
Compared to 1 year ago, LEGN has an improved debt to assets ratio.
LEGN Yearly Shares OutstandingLEGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
LEGN Yearly Total Debt VS Total AssetsLEGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 8.33 indicates that LEGN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.33, LEGN belongs to the top of the industry, outperforming 85.61% of the companies in the same industry.
LEGN has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
LEGN has a Debt to Equity ratio of 0.31. This is in the lower half of the industry: LEGN underperforms 71.94% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 8.33
ROIC/WACCN/A
WACC9.3%
LEGN Yearly LT Debt VS Equity VS FCFLEGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

2.3 Liquidity

A Current Ratio of 4.98 indicates that LEGN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.98, LEGN is in line with its industry, outperforming 53.82% of the companies in the same industry.
A Quick Ratio of 4.90 indicates that LEGN has no problem at all paying its short term obligations.
LEGN has a Quick ratio (4.90) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.98
Quick Ratio 4.9
LEGN Yearly Current Assets VS Current LiabilitesLEGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 500M 1B

More info and screens

7

3. Growth

3.1 Past

LEGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.74%, which is quite impressive.
LEGN shows a strong growth in Revenue. In the last year, the Revenue has grown by 61.20%.
Measured over the past years, LEGN shows a very strong growth in Revenue. The Revenue has been growing by 42.17% on average per year.
EPS 1Y (TTM)60.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)61.2%
Revenue growth 3Y56.08%
Revenue growth 5Y42.17%
Sales Q2Q%66.86%

3.2 Future

Based on estimates for the next years, LEGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.37% on average per year.
LEGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 53.85% yearly.
EPS Next Y48.14%
EPS Next 2Y27.86%
EPS Next 3Y32.52%
EPS Next 5Y17.37%
Revenue Next Year98.93%
Revenue Next 2Y81.21%
Revenue Next 3Y70.36%
Revenue Next 5Y53.85%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LEGN Yearly Revenue VS EstimatesLEGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
LEGN Yearly EPS VS EstimatesLEGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LEGN. In the last year negative earnings were reported.
Also next year LEGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LEGN Price Earnings VS Forward Price EarningsLEGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LEGN Per share dataLEGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as LEGN's earnings are expected to grow with 32.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.86%
EPS Next 3Y32.52%

More info and screens

0

5. Dividend

5.1 Amount

LEGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEGEND BIOTECH CORP-ADR

NASDAQ:LEGN (2/21/2025, 8:00:02 PM)

After market: 39.5 -0.2 (-0.5%)

39.7

+0.78 (+2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-10 2025-03-10/amc
Inst Owners55.57%
Inst Owner Change-92.87%
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap7.28B
Analysts83.33
Price Target81.09 (104.26%)
Short Float %13.95%
Short Ratio9.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.1%
Min EPS beat(2)-52.09%
Max EPS beat(2)74.28%
EPS beat(4)3
Avg EPS beat(4)9.14%
Min EPS beat(4)-52.09%
Max EPS beat(4)74.28%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)26.81%
Min Revenue beat(2)9.17%
Max Revenue beat(2)44.46%
Revenue beat(4)2
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-39.63%
Max Revenue beat(4)44.46%
Revenue beat(8)4
Avg Revenue beat(8)29.55%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.62%
PT rev (3m)-3.75%
EPS NQ rev (1m)-12.1%
EPS NQ rev (3m)-12.1%
EPS NY rev (1m)-43.03%
EPS NY rev (3m)-40.93%
Revenue NQ rev (1m)-0.95%
Revenue NQ rev (3m)-0.95%
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)5.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14
P/FCF N/A
P/OCF N/A
P/B 6.53
P/tB 6.54
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS2.84
BVpS6.08
TBVpS6.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.06%
ROE -31.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.88%
FCFM N/A
ROA(3y)-32.54%
ROA(5y)-33.85%
ROE(3y)-51.36%
ROE(5y)-53.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 84.78%
Cap/Sales 3.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.98
Quick Ratio 4.9
Altman-Z 8.33
F-Score4
WACC9.3%
ROIC/WACCN/A
Cap/Depr(3y)190.38%
Cap/Depr(5y)406.06%
Cap/Sales(3y)31.83%
Cap/Sales(5y)45.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y48.14%
EPS Next 2Y27.86%
EPS Next 3Y32.52%
EPS Next 5Y17.37%
Revenue 1Y (TTM)61.2%
Revenue growth 3Y56.08%
Revenue growth 5Y42.17%
Sales Q2Q%66.86%
Revenue Next Year98.93%
Revenue Next 2Y81.21%
Revenue Next 3Y70.36%
Revenue Next 5Y53.85%
EBIT growth 1Y54.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.36%
EBIT Next 3Y34.71%
EBIT Next 5Y25.73%
FCF growth 1Y-86.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-95.37%
OCF growth 3YN/A
OCF growth 5YN/A